Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
100%(10 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_3
4
36%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.9%
Most Advanced
Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

completed1091%
terminated19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

NCT00910624
completedphase_3

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

NCT00302081
completedphase_3

Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

NCT00048724
completedphase_3

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

NCT00049842
completed

PegIntron Injection Surveillance Plan (Study P04123)

NCT00723931
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00910624Phase 3

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

Completed
NCT00302081Phase 3

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Completed
NCT00048724Phase 3

Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

Completed
NCT00049842Phase 3

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

Completed
NCT00723931

PegIntron Injection Surveillance Plan (Study P04123)

Completed
NCT00723879

Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Terminated
NCT00704522

Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)

Completed
NCT00705666

Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)

Completed
NCT00724373

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

Completed
NCT00727259

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)

Completed
NCT00705263

Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)

Completed

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11